Evidence map›Paper›PMID 30845731›Full record

Trial reportNutrients2019

Serum Uric Acid-Lowering Effects of Combined Glycine and Tryptophan Treatments in Subjects with Mild Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.

Shunji Oshima, Sachie Shiiya, Yasunori Nakamura

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Microorganisms · 2024
    Article
  8. Increased prevalence of gout in patients with inflammatory bowel disease: A population-based study.JGH open : an open access journal of gastroenterology and hepatology · 2023
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shunji OshimaCore Technology Laboratories, Asahi Group Holdings, Ltd., 1-21, Midori 1-Chome, Moriya-shi 302-0106, Japan. shunji.oshima@asahigroup-holdings.com.ORCID 0000-0003-1810-8661
Sachie ShiiyaCore Technology Laboratories, Asahi Group Holdings, Ltd., 1-21, Midori 1-Chome, Moriya-shi 302-0106, Japan. sachie.siiya@asahigroup-holdings.com.
Yasunori NakamuraCore Technology Laboratories, Asahi Group Holdings, Ltd., 1-21, Midori 1-Chome, Moriya-shi 302-0106, Japan. yasunori.nakamura@asahigroup-holdings.com.
Asahi Breweries (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We determined the serum uric acid-lowering effects of combined daily supplementation of glycine and tryptophan in patients with mild hyperuricemia using a randomized, double-blind, placebo-controlled, crossover clinical trial design. Japanese healthy adult males and females with mild hyperuricemia (fasting serum uric acid of 6.6⁻7.9 mg/dL) ingested a powder mixture containing 3.0 g of glycine and 0.2 g of tryptophan or a placebo powder once daily at bedtime for 6 weeks. Combined supplementation with glycine and tryptophan significantly decreased serum uric acid levels (from 7.1 mg/dL to 6.7 mg/dL,

Indexed as

Dietary SupplementsCross-Over StudiesDouble-Blind MethodFemaleGlycineHumansHyperuricemiaMaleMiddle AgedPowdersTreatment OutcomeTriglyceridesTryptophanUric AcidGlycinePowdersTriglyceridesTryptophanUric Acidglycinetriglyceridetryptophanuric acidurinary pH

Identifiers

PMID30845731
PMCPMC6471320
OpenAlexW2920526442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.